Tofas to develop electric Doblo engine with Arcelik

July 25 (Reuters) – Turkish automaker Tofas (TOASO.IS) will develop the engine for an electric version of Fiat’s Doblo vehicle with Arcelik (ARCLK.IS) and be ready for production by mid-2011 if demand rises, Tofas said.

Tofas, in which Fiat (FIA.MI) and Turkish conglomerate Koc Holding (KCHOL.IS) each own 38 percent, plans to sell the car to European markets and could export it to the United States in the future, Tofas’s chief executive, Ali Pandir, told reporters.

Turkey’s automotive sector, the heart of its export industry, was hit last year by the sharp slowdown in key export markets in Europe and also weak domestic demand.

“Because we are the base for light commercial vehicle production and research and development, Fiat assigned the electrification of these vehicles to us,” Pandir said.

The cost of the electric Fiat Doblo EV prototype is put at 20 million euros ($25.75 million) and an investment of 5-10 million euros could be required for the manufacture of some 500-1,000 vehicles a year depending on demand from Europe.

“We will develop the electric engine together with Arcelik. Arcelik have know-how on the subject of electric engines and we have vehicle technology,” he said.

Turkey’s Arcelik is a household appliances manufacturer and Europe’s third-largest white goods maker. Conglomerate Koc owns some 40 percent of the company.

“We target mid-2011 for production (of the electric car), but it depends on market conditions,” said Tofas research and development director Kemal Yazici.

Tofas has for now shelved plans to export the regular Doblo to the United States due to market conditions, but could export the electric version if the market grows, Pandir said.

Tofas posted a net profit of 118.3 million lira in the first quarter, more than three times higher than the previous year’s profit, as its markets recovered from last year’s sharp decline. ($1=.7766 euros) (Writing by Daren Butler; Editing by Greg Mahlich)

Level 3 Connects New Transatlantic Route at Equinix London International Business Exchange Data Center

New Direct Backhaul Connection Improves Diversity and Lowers Latency Between UK
and North America
LONDON–(Business Wire)–
Equinix, Inc. (Nasdaq: EQIX), a provider of global data center services, and
Level 3 Communications, Inc. (NASDAQ: LVLT), a leading international provider of
fiber-based communications services, today announced the opening of a new access
node in Equinix`s International Business Exchange (IBX) London 4/London5 (LD4/5)
data center campus located on the outskirts of London. The access node will link
the Equinix LD4/5 IBX campus directly with three of Level 3`s transatlantic
routes to New York, improving diversity and lowering the latency on the route
between the UK and North America.

Level 3`s new access node will offer customers in the Equinix LD4/5 campus
direct connectivity to three transatlantic routes; Yellow, AC-1 and Apollo
North, as well as provide access to its extensive North American footprint via
the Level 3 facilities in New York. In addition, alongside the community of
networks, content and digital media companies, enterprises and financial service
providers already operating within Equinix`s LD4/5 campus, Level 3`s customers
will benefit from a new route that bypasses central London. By locating the
access node on the outskirts of London, Level 3 has improved the resilience and
speed of connection between London and the U.S.

“We live in an increasingly connected world where the speed and reliability with
which information travels – particularly for financial firms – is critical to
successful business operations,” said James Heard, president of European Markets
at Level 3. “Our collaboration with Equinix is the latest example of Level 3`s
commitment to expanding its low-latency offerings across the Atlantic, enabling
more options for transatlantic connectivity independent of central London, and
providing top-quality solutions for the most demanding of international
enterprise customers.”

Level 3 currently serves 20 European countries and operates an extensive and
diverse network footprint across North America and Europe. The new direct
transatlantic routes and on-net connectivity will also provide customers in
Equinix`s LD4/5 campus greater flexibility to scale bandwidth directly connected
to the Level 3 transatlantic network as their demand increases.

“Equinix provides state-of-the-art colocation, interconnection and exchange
services that securely connect the world`s networks, enterprises, cloud
providers and financial institutions,” said Russell Poole, General Manager,
Equinix UK. “The availability of Level 3`s new service at our LD4/5 IBX campus
is a valuable addition to our offering and presents an attractive value
proposition for customers operating within our ecosystems.”

About Level 3 Communications

Level 3 Communications, Inc. (NASDAQ: LVLT) is a leading international provider
of fiber-based communications services. Enterprise, content, wholesale and
government customers rely on Level 3 to deliver services with an
industry-leading combination of scalability and value over an end-to-end fiber
network. Level 3 offers a portfolio of metro and long-haul services, including
transport, data, Internet, content delivery and voice. For more information,
visit www.Level3.com.

Forward-Looking Statement

Some of the statements made in this press release are forward looking in nature.
These statements are based on management`s current expectations or beliefs.
These forward looking statements are not a guarantee of performance and are
subject to a number of uncertainties and other factors, many of which are
outside Level 3`s control, which could cause actual events to differ materially
from those expressed or implied by the statements. The most important factors
that could prevent Level 3 from achieving its stated goals include, but are not
limited to, the current uncertainty in the global financial markets and the
global economy; disruptions in the financial markets that could affect Level 3`s
ability to obtain additional financing; as well as the company`s ability to:
increase and maintain the volume of traffic on the network; successfully
integrate acquisitions; develop effective business support systems; defend
intellectual property and proprietary rights; manage system and network failures
or disruptions; develop new services that meet customer demands and generate
acceptable margins; adapt to rapid technological changes that lead to further
competition; attract and retain qualified management and other personnel; and
meet all of the terms and conditions of debt obligations. Additional information
concerning these and other important factors can be found within Level 3`s
filings with the Securities and Exchange Commission. Statements in this press
release should be evaluated in light of these important factors. Level 3 is
under no obligation to, and expressly disclaims any such obligation to, update
or alter its forward-looking statements, whether as a result of new information,
future events, or otherwise.

About Equinix

Equinix, Inc. (Nasdaq: EQIX) provides global data center services that ensure
the vitality of the information-driven world. Global enterprises, content and
financial companies, and more than 575 network service providers rely upon
Equinix`s insight and expertise to protect and connect their most valued
information assets. Equinix operates 87 International Business Exchange (IBX)
and partner data centers across 35 metro areas in North America, Europe and
Asia-Pacific.

Important information about Equinix is routinely posted on the investor
relations page of its Web site located at http://www.equinix.com/investors. We
encourage you to check Equinix`s website regularly for the most up-to-date
information.

Forward Looking Statements

This press release contains forward-looking statements that involve risks and
uncertainties. Actual results may differ materially from expectations discussed
in such forward-looking statements. Factors that might cause such differences
include, but are not limited to, the challenges of acquiring, operating and
constructing IBX centers and developing, deploying and delivering Equinix
services; unanticipated costs or difficulties relating to the integration of
companies we have acquired or will acquire into Equinix; a failure to receive
significant revenue from customers in recently built out or acquired data
centers; failure to complete any financing arrangements contemplated from time
to time; competition from existing and new competitors; the ability to generate
sufficient cash flow or otherwise obtain funds to repay new or outstanding
indebtedness; the loss or decline in business from our key customers; and other
risks described from time to time in Equinix’s filings with the Securities and
Exchange Commission. In particular, see Equinix’s recent quarterly and annual
reports filed with the Securities and Exchange Commission, copies of which are
available upon request from Equinix. Equinix does not assume any obligation to
update the forward-looking information contained in this press release.

Equinix and IBX are registered trademarks of Equinix, Inc. International
Business Exchange is a trademark of Equinix, Inc.

Level 3
Media Contact:
Alexis Hammack, 720-888-2441
alexis.hammack@level3.com
or
Investor Contact:
Mark Stoutenberg, 720-888-2518
mark.stoutenberg@level3.com
or
Equinix Contact (Global)
Joan Powell, 650-513-7098
joanpowell@equinix.com
or
Equinix Contact (Europe)
Johnson King
Jacqui Depares or Ben Roberts, +44 (0) 20 7401 7968
Equinixteam@johnsonking.co.uk

Copyright Business Wire 2010

Swedish Orphan Biovitrum and Dongbao announce Commercial Alliance for the Chinese and European markets

STOCKHOLM, SWEDEN, Jul 06 (MARKET WIRE) —

Stockholm, Sweden and Tonghua, China – July 6, 2010 – Swedish Orphan
Biovitrum (STO: SOBI) and Dongbao today announced their intent to form a
strategic Commercial Alliance. In such an alliance, Swedish Orphan
Biovitrum would be the marketing and sales partner of choice for
Dongbao’s pipeline of Biopharmaceuticals and other drugs in Europe and
Dongbao would be the marketing and sales partner of choice for Swedish
Orphan Biovitrum’s marketed and pipeline products in China.

The announced Commercial Alliance would be a partnership where both
parties will benefit in two ways. First, each party secures a marketing
and sales partner for its own products in an important new territory,
China in the case of Swedish Orphan Biovitrum and Europe in the case of
Dongbao. Second, each party gains access to a new portfolio of exciting
products for its home markets.

The parties also announced that they intend to complete the first stage of
the Commercial Alliance by completing ongoing negotiations regarding the
following products:

* Iron Sucrose from Dongbao where Swedish Orphan Biovitrum will be the
exclusive marketing and sales partner in Europe for this product.

* Kineret and the late stage development project Kiobrina from Swedish
Orphan Biovitrum where Dongbao will be the exclusive marketing and sales
partner in China for these products.

Swedish Orphan Biovitrum intends to deepen its collaboration with Dongbao,
including its affiliate Rechon Life Science Group, as regards
manufacturing services.

An alliance will address current pharmaceutical market trends in both
China and Europe. The Chinese pharmaceutical market is large and rapidly
growing. It is also becoming more and more receptive to high value,
innovative products that meet significant unmet medical needs. Thus,
Swedish Orphan Biovitrum’s products are a good fit with the strong and
growing high value, specialty segment of the Chinese market. Similarly,
the Biosuperior segment of the European pharmaceutical market is rapidly
growing. Again, this makes market entry in Europe for Dongbao’s portfolio
of Biosuperiors timely and in-line with regional trends.

Martin Nicklasson, CEO of Swedish Orphan Biovitrum stated “We are very
pleased to have identified a partner in Dongbao with a successful track
record of selling high value biotechnology products in China. Dongbao has
a deep understanding of biotechnology products from a manufacturing and
clinical development perspective. Moreover, they have an impressive track
record of success in regulatory affairs as well as in marketing and
sales. Thus, we see Dongbao as the perfect partner to help Swedish Orphan
Biovitrum to realize the significant opportunity for our products in the
Chinese market.

Additionally, we are excited about gaining access to Dongbao’s pipeline of
high value Biosuperiors. We look forward to working with these products
over the long term to realize the full commercial potential of these
products in Europe.”

Dr. Zhaoqi Li, Vice President of Dongbao Enterprise Group and the Chairman
of the Board of Rechon Life Science Group expressed that “A fast growing
Chinese market is now offering great opportunity for innovative and high
value pharmaceutical products. We admire Swedish Orphan Biovitrum’s
remarkable efforts and achievements in the development of specialist
pharmaceutical products for rare diseases. We will contribute, with the
best of our effort, to the successful introduction of Swedish Orphan
Biovitrum’s product into the Chinese market as well as into the emerging
markets where Dongbao/Rechon already have a strong network established.

It has been a very interesting journey made by Dongbao in the development
of high value biotech products. By combining Swedish Orphan Biovitrum’s
knowledge, experience and market network with Dongbao’s interesting range
of biotech products we will have a prosperous future in Europe.

Partnership has always been important for Dongbao’s business success. The
establishment of a strong collaboration with Swedish Orphan Biovitrum will
add good value for our future development. We are very excited that such a
Commercial Alliance with Swedish Orphan Biovitrum will enable smooth
access of our products into the European market and, in the other
direction, we are very pleased to offer our support for the successful
entry of Swedish Orphan Biovitrum’s products into the Chinese market.”

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum is a Swedish based niche specialty pharmaceutical
company with an international market presence. The company is focused on
providing and developing specialist pharmaceuticals for rare disease
patients with high medical needs. The portfolio consists of about 60
marketed products and an emerging late stage clinical development
pipe-line. Our focus areas are: hemophilia, inflammation/autoimmune
diseases, fat malabsorption, cancer supportive care and inherited
metabolic disorders.

Swedish Orphan Biovitrum had pro-forma revenues 2009e of about 2 BSEK and
approximately 500 employees. The head office is located in Sweden and the
share (STO: SOBI) is listed on NASDAQ OMX Stockholm. For more information
please visit www.sobi.com.

For more information please contact: Swedish Orphan Biovitrum AB (publ):

Martin Nicklasson, CEO
Phone: +46 8 697 20 00

Erik Kinnman, VP Investor Relations
Phone: +46 73 422 15 40
E-mailerik.kinnman@sobi.com

Swedish Orphan Biovitrum may be required to disclose the information
provided herein pursuant to the Swedish Securities Markets Act. The
information was provided for public release on July 6, 2010 at 8:30 a.m.
CET.

[HUG#1429736]

Press release July 6, 2010:

http://hugin.info/134557/R/1429736/376773.pdf

This announcement is
distributed by Thomson Reuters on behalf of Thomson Reuters clients. The
owner of this announcement warrants that: (i) the releases contained
herein are protected by copyright and other applicable laws; and (ii)
they are solely responsible for the content, accuracy and originality of
the information contained therein. All reproduction for further
distribution is prohibited.

Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE

Copyright 2010, Market Wire, All rights reserved.

Swedish Orphan Biovitrum AB (publ): Swedish Orphan Biovitrum and Dongbao announce Commercial Alliance for the Chinese and European markets

Stockholm, Sweden and Tonghua, China – July 6, 2010 – Swedish Orphan Biovitrum (STO:
SOBI) and Dongbao today announced their intent to form a strategic Commercial Alliance.
In such an alliance, Swedish Orphan Biovitrum would be the marketing and sales partner
of choice for Dongbao’s pipeline of Biopharmaceuticals and other drugs in Europe and
Dongbao would be the marketing and sales partner of choice for Swedish Orphan
Biovitrum’s marketed and pipeline products in China.

The announced Commercial Alliance would be a partnership where both parties will benefit
in two ways. First, each party secures a marketing and sales partner for its own
products in an important new territory, China in the case of Swedish Orphan Biovitrum
and Europe in the case of Dongbao. Second, each party gains access to a new portfolio
of exciting products for its home markets.

The parties also announced that they intend to complete the first stage of the
Commercial Alliance by completing ongoing negotiations regarding the following
products:

*

Iron Sucrose from Dongbao where Swedish Orphan Biovitrum will be the exclusive marketing
and sales partner in Europe for this product.

*

Kineret and the late stage development project Kiobrina from Swedish Orphan Biovitrum
where Dongbao will be the exclusive marketing and sales partner in China for these
products.

Swedish Orphan Biovitrum intends to deepen its collaboration with Dongbao, including its
affiliate Rechon Life Science Group, as regards manufacturing services.

An alliance will address current pharmaceutical market trends in both China and Europe.
The Chinese pharmaceutical market is large and rapidly growing. It is also becoming
more and more receptive to high value, innovative products that meet significant unmet
medical needs. Thus, Swedish Orphan Biovitrum’s products are a good fit with the strong
and growing high value, specialty segment of the Chinese market. Similarly, the
Biosuperior segment of the European pharmaceutical market is rapidly growing. Again,
this makes market entry in Europe for Dongbao’s portfolio of Biosuperiors timely and
in-line with regional trends.

Martin Nicklasson, CEO of Swedish Orphan Biovitrum stated “We are very pleased to have
identified a partner in Dongbao with a successful track record of selling high value
biotechnology products in China. Dongbao has a deep understanding of biotechnology
products from a manufacturing and clinical development perspective. Moreover, they have
an impressive track record of success in regulatory affairs as well as in marketing and
sales. Thus, we see Dongbao as the perfect partner to help Swedish Orphan Biovitrum to
realize the significant opportunity for our products in the Chinese market.

Additionally, we are excited about gaining access to Dongbao’s pipeline of high value
Biosuperiors. We look forward to working with these products over the long term to
realize the full commercial potential of these products in Europe.”

Dr. Zhaoqi Li, Vice President of Dongbao Enterprise Group and the Chairman of the Board
of Rechon Life Science Group expressed that “A fast growing Chinese market is now
offering great opportunity for innovative and high value pharmaceutical products. We
admire Swedish Orphan Biovitrum’s remarkable efforts and achievements in the development
of specialist pharmaceutical products for rare diseases. We will contribute, with the
best of our effort, to the successful introduction of Swedish Orphan Biovitrum’s product
into the Chinese market as well as into the emerging markets where Dongbao/Rechon
already have a strong network established.

It has been a very interesting journey made by Dongbao in the development of high value
biotech products. By combining Swedish Orphan Biovitrum’s knowledge, experience and
market network with Dongbao’s interesting range of biotech products we will have a
prosperous future in Europe.

Partnership has always been important for Dongbao’s business success. The establishment
of a strong collaboration with Swedish Orphan Biovitrum will add good value for our
future development. We are very excited that such a Commercial Alliance with Swedish
Orphan Biovitrum will enable smooth access of our products into the European market and,
in the other direction, we are very pleased to offer our support for the successful
entry of Swedish Orphan Biovitrum’s products into the Chinese market.”

About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum is a Swedish based niche specialty pharmaceutical company with
an international market presence. The company is focused on providing and developing
specialist pharmaceuticals for rare disease patients with high medical needs. The
portfolio consists of about 60 marketed products and an emerging late stage clinical
development pipe-line. Our focus areas are: hemophilia, inflammation/autoimmune
diseases, fat malabsorption, cancer supportive care and inherited metabolic disorders.

Swedish Orphan Biovitrum had pro-forma revenues 2009e of about 2 BSEK and approximately
500 employees. The head office is located in Sweden and the share (STO: SOBI) is listed
on NASDAQ OMX Stockholm. For more information please visit www.sobi.com
http://www.sobi.com/ .

For more information please contact: Swedish Orphan Biovitrum AB (publ):

Martin Nicklasson, CEO
Phone: +46 8 697 20 00

Erik Kinnman, VP Investor Relations
Phone: +46 73 422 15 40
E-mail erik.kinnman@sobi.com mailto:erik.kinnman@sobi.com

Swedish Orphan Biovitrum may be required to disclose the information provided herein
pursuant to the Swedish Securities Markets Act. The information was provided for public
release on July 6, 2010 at 8:30 a.m. CET.

HUG#1429736

Press release July 6, 2010 http://hugin.info/134557/R/1429736/376773.pdf

Research and Markets: European Markets for Coronary Artery Bypass Graft Devices to 2013

DUBLIN–(Business Wire)–
Research and Markets
(http://www.researchandmarkets.com/research/c1e3ef/european_markets_f) has
announced the addition of the “European Markets for Coronary Artery Bypass Graft
Devices 2009″ report to their offering.

Through 2013, the market for coronary artery bypass graft (CABG) devices in
Europe will be driven largely by an increase in procedure volumes caused by
rising rates of coronary artery disease (CAD) and a growing need for repeat
revascularization procedures. Although the market will be limited by less
invasive alternative treatments, such as medical managment and percutaneous
coronary interventions, growing adoption of endoscopic vessel harvesting (EVH)
devices and anastomosis assist devices (AADs) will further support revenue
growth over the forecast period.

Questions Answered in This Report:

The global economic downturn beginning in late 2008 had a broad impact on
European CABG device markets. How have budget restrictions affected the
replacement rate of capital equipment required for CABG procedures? How long
will this impact continue to be felt in the CABG device market?

Cardiac surgeons across Europe are increasingly opting for off-pump coronary
artery bypass (OPCAB) over on-pump coronary artery bypass (ONCAB) methods. How
rapidly is this shift occuring? Will OPCAB completely replace ONCAB? For which
patient subgroups might ONCAB still have a role?

Treatment of CAD by CABG is in direct competition with interventional cardiology
methods. What clinical studies are affecting physicians’ choices? How will the
introduction and adoption of EVH and minimally invasive CABG devices affect this
rivalry?

The competitive landscape of the European CABG device market is highly dynamic.
How have companies used acquisitions to reshape or expand their portfolios? How
do the competitive landscapes of the covered countries differ?

Scope:

Regions covered: France, Germany, Italy, and the UK

Segmentation: Our analysis uses the following segmentation of the market:

* Cardiac surgery labs
* ONCAB devices
* – Disposable perfusion devices (custom perfusion pack and stand-alone:
arterial filters, cardioplegia systems, centrifugal blood pumps,
hemoconcentrators, oxygenators, reservoirs, mini-bypass circuits, and cannulae)
* – Capital equipment (cardiopulmonary bypass machines and centrifugal pump
controllers)
* OPCAB devices
* – Primary devices (stabilizers, positioners, and OPCAB kits)
* – Accessories (blowers/misters and coronary shunts)
* EVH devices
* – Saphenous vein procedures
* – Radial artery procedures
* AADs
* – Proximal (hemostatic seal systems and automated graft delivery system)
* – Distal

Market forecast features: Based on primary research with industry professionals,
we use our proprietary forecasting model to provide an in-depth examination of
current and future trends in procedure volumes, unit sales, average selling
prices, and market values over a 7-year period (20072013).

Competitive analysis: We provide a detailed analysis of the competitive
landscape in the market, as well as market shares and qualitative discussions of
the leading competitors in each market segment.

Key Topics Covered:

TABLE OF CONTENTS

LIST OF EXHIBITS

EXECUTIVE SUMMARY

METHODOLOGY

1.0 EUROPEAN CORONARY ARTERY BYPASS GRAFT DEVICE MARKET

2.0 ON-PUMP CORONARY ARTERY BYPASS DEVICE MARKET

3.0 OFF-PUMP CORONARY ARTERY BYPASS DEVICE MARKET

4.0 ENDOSCOPIC VESSEL HARVESTING DEVICE MARKET

5.0 ANASTOMOSIS ASSIST DEVICE MARKET

APPENDIX A: MRG ACRONYMS AND INITIALISMS

APPENDIX B: SUPPLEMENTAL EXHIBITS

For more information visit

http://www.researchandmarkets.com/research/c1e3ef/european_markets_f

Source: Millennium Research Group

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Copyright Business Wire 2010

EURO BONDS-BAT dual tranche bond

June 25 (Reuters) – News, details on corporate bond issues in the European markets on Friday:

Stocks | Bonds | Global Markets

BAT (BATS.L)

Issue: Cigarette maker British American Tobacco is selling a dual-tranche bond, an official with one of the banks managing the sale said. The deal comprises a 10-year 600 million euro bond and a 30-year 275 million pound bond.

Managing banks: BNP Paribas, Deutsche Bank, HSBC, JP Morgan, Lloyds.

Rating: Moody’s Baa1, S&P BBB+ and Fitch BBB+

(London Corporate Finance: +44 207 542 8389)

European shares edge up on banks; G20 awaited

June 25 (Reuters) – European shares edged higher on Friday after three-sessions of losses though gains were limited as investors took caution ahead of the weekend G20 meeting and concerns over tougher financial regulation.

Stocks | European Markets | Global Markets

Banks provided the index with some support following sharp falls in the previous session. U.S. lawmakers on Friday neared a breakthrough in their historic rewrite of financial regulations as they agreed to tough new limits on banks’ trading activity.

HSBC (HSBA.L), Standard Chartered (STAN.L) and Societe Generale (SOGN.PA) rose 0.9 to 1.1 percent.

By 0723 GMT, the pan-European FTSEurofirst 300 .FTEU3 index of top shares was up 0.1 percent at 1,020.86 points, but trading was choppy. “A nervous morning ahead of the G20, no one is really wanting to take any big positions ahead of the G20,” said Justin Urquhart Stewart, director at Seven Investment Management. “There are little reasons for the market to drive higher today.”

Energy stocks featured among the worst performers, with BP (BP.L) slipping 0.6 percent. The Gulf of Mexico oil spill has entered its 67th day on Friday and with bad weather looming, clean-up and containment efforts could be hampered.

(Reporting by Joanne Frearson)

European shares turn negative; miners fall

June 24 (Reuters) – European shares turned negative on Thursday morning, with miners giving up gains from early in the session, having risen on hopes Australia’s new Prime Minister would compromise on proposed taxes on resource firms.

Stocks | European Markets | Global Markets

At 0730 GMT, the FTSEurofirst 300 .FTEU3 index of top European shares was down 0.4 percent at 1,035.76 points.

BHP Billiton (BLT.L), Kazakhmys (KAZ.L), Rio Tinto (RIO.L) and Xstrata (XTA.L) were between 1 and 2.7 percent lower. (Reporting by Brian Gorman)

European stock index futures signal losses

June 22 (Reuters) – European stock index futures pointed to a lower open on Tuesday as a dip on Wall Street and in Asia prompt investors to cash in some profits after a brisk nine-session winning streak.

Stocks | European Markets | Global Markets | Financials

By 0602 GMT, futures for the STOXX Europe 50 STXEc1, for Germany’s DAX FDXc1 and for France’s CAC FCEc1 were down 0.3-0.9 percent.

Bookies see Europe stocks snapping winning run

June 22 (Reuters) – Financial bookmakers expect to see the leading European benchmark indexes falling on Tuesday as losses on Wall Street and in Asia prompt investors to cash in some profits after a nine-session winning streak.

Stocks | European Markets | Global Markets | Financials

Financial spreadbetters expect Britain’s FTSE 100 .FTSE to open 42 to 48 points lower, or as much as 0.9 percent, Germany’s DAX .GDAXI to open 31 to 38 points lower, or as much as 0.6 percent, and France’s CAC-40 .FCHI to open 34 to 39 points lower, or as much as 1 percent. (Reporting by Blaise Robinson; Editing by James Regan)

European stock index futures signal falls

June 17 (Reuters) – European stock index futures pointed to a lower open on Thursday, halting a six-session rally as investors remained cautious ahead of a Spanish bond auction.

Stocks | European Markets | Global Markets

By 0604 GMT, futures for the STOXX Europe 50 STXEc1, for Germany’s DAX FDXc1 and for France’s CAC FCEc1 were down 0.1 to 0.2 percent. (Reporting by Harpreet Bhal)

European stock index futures signal more gains

June 16 (Reuters) – European stock index futures pointed to a higher open on Wednesday, as stocks were poised to rise for a sixth straight session, mirroring a strong rally on Wall Street.

Stocks | European Markets | Global Markets | Financials

By 0603 GMT, futures for the STOXX Europe 50 STXEc1, for Germany’s DAX FDXc1 and for France’s CAC FCEc1 were up 0.5-0.9 percent.

On Wall Street on Tuesday, the S&P 500 .SPX added 2.4 percent, turning positive for the year and rising above its 200-day moving average for the first time in a month, a milestone that could be seen as a signal the recent downtrend may be nearing an end. (Reporting by Blaise Robinson)

Bookies see Europe stocks extending rally

June 16 (Reuters) – Financial bookmakers expected to see the leading European benchmark indexes rising on Wednesday, climbing for a sixth session in a row and tracking a strong rally on Wall Street.

Stocks | European Markets | Global Markets | Financials

Financial spreadbetters expected Britain’s FTSE 100 .FTSE to open 43 to 45 points higher, or as much as 0.9 percent, Germany’s DAX .GDAXI to open 26 to 32 points higher, or as much as 0.5 percent, and France’s CAC-40 .FCHI to open 30 to 31 points higher, or as much as 0.9 percent.

The S&P 500 turned positive for the year on Tuesday and rose above its 200-day moving average for the first time in a month, suggesting the recent downtrend may be nearing an end.

(Reporting by Blaise Robinson)

European stock index futures signal early losses

June 15 (Reuters) – European stock index futures pointed to a lower open on Tuesday, as a downgrade of Greece’s credit rating prompts investors to cash in some of the hefty gains made over the past four sessions.

Stocks | European Markets | Global Markets | Financials

By 0601 GMT, futures for the STOXX Europe 50 STXEc1, for Germany’s DAX FDXc1 and for France’s CAC FCEc1 were down 0.3-0.6 percent.

(Reporting by Blaise Robinson)

Basilea announces distribution agreement with Almirall for Toctino(R) in selected European markets and Mexico

BASEL, SWITZERLAND, Jun 15 (MARKET WIRE) —
Basilea Pharmaceutica AG / Basilea announces distribution agreement with
Almirall for Toctino(R) in selected European markets and Mexico processed
and transmitted by Hugin AS. The issuer is solely responsible for the
content of this announcement.

Basilea Pharmaceutica Ltd. (SWISS: BSLN) announced today that Basilea
Pharmaceutica International Ltd. has entered into an exclusive
distribution agreement with Almirall, S.A. for Basilea’s Toctino(R)
(alitretinoin), a once-daily oral treatment for adults with severe chronic
hand eczema unresponsive to potent topical corticosteroids, in selected
European markets and Mexico.

Basilea has appointed Almirall as its exclusive distributor for
Toctino(R) in Austria, Belgium, Czech Republic, Italy, Luxembourg,
Mexico, the Netherlands, Poland, Portugal, Slovakia and Spain. Basilea
retains the future right to co-promote Toctino(R) in selected markets
covered under the agreement.

Under the terms of the agreement, Basilea will be eligible for upfront and
milestone payments totaling EUR 27 million, including up to EUR 16 million
in upfront payments and milestones related to the launch of Toctino(R) in
two key markets of the territory.

“We are very pleased to further expand the commercial availability of
Toctino through this partnership with Almirall, a leading dermatology
company in Europe. Almirall has a well-established and significant sales
force with a successful track record in markets where Basilea has not yet
established a full commercial sales presence, including in Almirall’s
home market Spain,” said Dr. Anthony Man, CEO Basilea Pharmaceutica Ltd.
“Through this partnership Toctino will be available sooner and to more
patients than otherwise possible in these selected markets.”

About Toctino(R) (alitretinoin)

Toctino(R) was developed by Basilea Pharmaceutica International Ltd.

To date, Toctino(R) is marketed in Denmark, France, Germany, Switzerland
and the United Kingdom for the treatment of severe chronic hand eczema
(CHE). The drug is approved in 15 additional European countries as well
as in Canada and has been recommended for approval in seven further
European countries.

In the largest ever phase III clinical trial program in CHE, Toctino(R)
was the first treatment to show effective clearing of severe CHE
unresponsive to potent topical corticosteroids, with clear or almost
clear hands achieved in nearly 50 percent of patients treated with 30 mg
Toctino(R). The once-daily oral therapy for adults is given for 12 to 24
weeks, depending on patient response, and six- month post-treatment
observations in patients who responded to Toctino(R) indicate that
treatment can provide long periods free from relapse and improve patient
satisfaction.

Toctino(R) is a known teratogen (a substance that can cause birth defects
when women are exposed during pregnancy). Strict pregnancy prevention one
month before, during, and one month after cessation of treatment as well
as monthly pregnancy testing are required for women of childbearing age. A
comprehensive pregnancy prevention program for Toctino(R) has been
developed and implemented.

In clinical trials, Toctino(R) was well tolerated and demonstrated a
safety profile overall consistent with the retinoid class. Overall, the
most frequently reported adverse events in the phase III clinical trials
were headache and increased levels of blood lipids. Side effects were
dose-dependent and reversible.

About chronic hand eczema

Hand eczema is a common inflammatory skin disease and is often chronic and
relapsing. Hand eczema is reported to affect up to ten percent of the
general population. The more severe, chronic form of the condition is
thought to affect five to seven percent of these patients, causing
impaired use of their hands and a considerable impact on their ability to
perform everyday activities.

Conference call

Basilea Pharmaceutica Ltd. invites you to participate in a conference call
on Tuesday, June 15, 4 p.m. (CEST), during which the company will discuss
today’s press release.

Dial-in numbers are:

+41 (0) 91 610 56 00 (Europe and ROW)

+1 (1) 866 291 4166 (USA)

+44 (0) 207 107 0611 (UK)

A playback will be available 1 hour after
the conference call until Thursday, June 17, 6 p.m. (CEST). Participants
requesting a digital playback may dial:

+41 (0) 91 612 4330 (Europe)

+1 (1) 866 416 2558 (USA)

+44 (0) 207 108 6233 (UK)

and will be asked to enter the ID 10274 followed by the # sign.

About Basilea

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and
listed on the SIX Swiss Exchange (SWISS: BSLN). Basilea’s products are
targeted to satisfy high medical and patient needs in the hospital and
specialty care setting. Its integrated research and development
operations are currently focused on antibiotics and antifungals, as well
as on the development of dermatology and oncology drugs, all areas in
which the medical challenge of rising resistance or non-response to
current treatment options is commonly encountered. The company owns a
broad and diversified portfolio. Basilea is marketing Toctino(R)
(alitretinoin), for the treatment of severe chronic hand eczema, in
Denmark, France, Germany, Switzerland and the United Kingdom. The drug is
approved in 15 additional European countries as well as in Canada and has
been recommended for approval in seven further European countries.
Furthermore, a phase III clinical trial on alitretinoin for the treatment
of severe chronic hand eczema is ongoing in the U.S. Basilea has entered
into a license, co-development and co-promotion agreement with Astellas
Pharma Inc. for its phase III compound isavuconazole for the treatment of
life-threatening invasive fungal infections on a worldwide basis,
including an option for Japan. Full rights to a third late-stage product,
ceftobiprole for the treatment of potentially life-threatening resistant
bacterial infections, will be transferred from Cilag GmbH International,
a Johnson & Johnson company, back to Basilea.

Disclaimer

This communication expressly or implicitly contains certain
forward-looking statements concerning Basilea Pharmaceutica Ltd. and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors, which could cause the actual results,
financial condition, performance or achievements of Basilea Pharmaceutica
Ltd. to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Basilea Pharmaceutica Ltd. is providing this communication as of this
date and does not undertake to update any forward-looking statements
contained herein as a result of new information, future events or
otherwise.

For further information, please contact:

+————————————-+———————————–+

|Media Relations |Investor Relations |
+————————————-+———————————–+
|Adesh Kaul |Barbara Zink, Ph.D., MBA |
|Head Public Relations & |Head Corporate Development |
|Corporate Communications | |
|+41 61 606 1460 |+41 61 606 1233 |
|media_relations@basilea.com |investor_relations@basilea.com |
| | |
| | |
+————————————-+———————————–+

This press release can be downloaded from www.basilea.com

[HUG#1423867]

— End of Message —

Basilea Pharmaceutica AG Grenzacherstrasse 487
P.O Box Basel Switzerland

ISIN: CH0011432447; Listed: Freiverkehr in Boerse Stuttgart, Freiverkehr
in Boerse Berlin, Open Market (Freiverkehr) in Frankfurter
Wertpapierboerse, Freiverkehr in Bayerische Boerse Muenchen;

Press
release (PDF): http://hugin.info/134390/R/1423867/372613.pdf

Copyright 2010, Market Wire, All rights reserved.

Basilea Pharmaceutica AG: Basilea announces distribution agreement with Almirall for Toctino® in selected European markets and Mexico

Basilea Pharmaceutica AG / Basilea announces distribution agreement with Almirall for
Toctino in selected European markets and Mexico processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this announcement.

Basel, Switzerland, June 15, 2010 – Basilea Pharmaceutica Ltd. (SIX:BSLN) announced
today that Basilea Pharmaceutica International Ltd. has entered into an exclusive
distribution agreement with Almirall, S.A. for Basilea’s Toctino (alitretinoin), a
once-daily oral treatment for adults with severe chronic hand eczema unresponsive to
potent topical corticosteroids, in selected European markets and Mexico.

Basilea has appointed Almirall as its exclusive distributor for Toctino in Austria,
Belgium, Czech Republic, Italy, Luxembourg, Mexico, the Netherlands, Poland, Portugal,
Slovakia and Spain. Basilea retains the future right to co-promote Toctino in selected
markets covered under the agreement.

Under the terms of the agreement, Basilea will be eligible for upfront and milestone
payments totaling EUR 27 million, including up to EUR 16 million in upfront payments and
milestones related to the launch of Toctino in two key markets of the territory.

“We are very pleased to further expand the commercial availability of Toctino through
this partnership with Almirall, a leading dermatology company in Europe. Almirall has a
well-established and significant sales force with a successful track record in markets
where Basilea has not yet established a full commercial sales presence, including in
Almirall’s home market Spain,” said Dr. Anthony Man, CEO Basilea Pharmaceutica Ltd.
“Through this partnership Toctino will be available sooner and to more patients than
otherwise possible in these selected markets.”

About Toctino (alitretinoin)

Toctino was developed by Basilea Pharmaceutica International Ltd.

To date, Toctino is marketed in Denmark, France, Germany, Switzerland and the United
Kingdom for the treatment of severe chronic hand eczema (CHE). The drug is approved in
15 additional European countries as well as in Canada and has been recommended for
approval in seven further European countries.

In the largest ever phase III clinical trial program in CHE, Toctino was the first
treatment to show effective clearing of severe CHE unresponsive to potent topical
corticosteroids, with clear or almost clear hands achieved in nearly 50 percent of
patients treated with 30 mg Toctino. The once-daily oral therapy for adults is given for
12 to 24 weeks, depending on patient response, and six-month post-treatment observations
in patients who responded to Toctino indicate that treatment can provide long periods
free from relapse and improve patient satisfaction.

Toctino is a known teratogen (a substance that can cause birth defects when women are
exposed during pregnancy). Strict pregnancy prevention one month before, during, and one
month after cessation of treatment as well as monthly pregnancy testing are required for
women of childbearing age. A comprehensive pregnancy prevention program for Toctino has
been developed and implemented.

In clinical trials, Toctino was well tolerated and demonstrated a safety profile overall
consistent with the retinoid class. Overall, the most frequently reported adverse events
in the phase III clinical trials were headache and increased levels of blood lipids.
Side effects were dose-dependent and reversible.

About chronic hand eczema

Hand eczema is a common inflammatory skin disease and is often chronic and relapsing.
Hand eczema is reported to affect up to ten percent of the general population. The more
severe, chronic form of the condition is thought to affect five to seven percent of
these patients, causing impaired use of their hands and a considerable impact on their
ability to perform everyday activities.

Conference call

Basilea Pharmaceutica Ltd. invites you to participate in a conference call on Tuesday,
June 15, 4 p.m. (CEST), during which the company will discuss today’s press release.

Dial-in numbers are:
+41 (0) 91 610 56 00 (Europe and ROW)
+1 (1) 866 291 4166 (USA)
+44 (0) 207 107 0611 (UK)

A playback will be available 1 hour after the conference call until Thursday, June 17, 6
p.m. (CEST). Participants requesting a digital playback may dial:

+41 (0) 91 612 4330 (Europe)
+1 (1) 866 416 2558 (USA)
+44 (0) 207 108 6233 (UK)

and will be asked to enter the ID 10274 followed by the # sign.

About Basilea

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX
Swiss Exchange (SIX:BSLN). Basilea’s products are targeted to satisfy high medical and
patient needs in the hospital and specialty care setting. Its integrated research and
development operations are currently focused on antibiotics and antifungals, as well as
on the development of dermatology and oncology drugs, all areas in which the medical
challenge of rising resistance or non-response to current treatment options is commonly
encountered.
The company owns a broad and diversified portfolio. Basilea is marketing Toctino
(alitretinoin), for the treatment of severe chronic hand eczema, in Denmark, France,
Germany, Switzerland and the United Kingdom. The drug is approved in 15 additional
European countries as well as in Canada and has been recommended for approval in seven
further European countries. Furthermore, a phase III clinical trial on alitretinoin for
the treatment of severe chronic hand eczema is ongoing in the U.S. Basilea has entered
into a license, co-development and co-promotion agreement with Astellas Pharma Inc. for
its phase III compound isavuconazole for the treatment of life-threatening invasive
fungal infections on a worldwide basis, including an option for Japan. Full rights to a
third late-stage product, ceftobiprole for the treatment of potentially life-threatening
resistant bacterial infections, will be transferred from Cilag GmbH International, a
Johnson & Johnson company, back to Basilea.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements
concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the actual
results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd.
to be materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is
providing this communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new information, future
events or otherwise.

For further information, please contact:

Media Relations Investor Relations
Adesh Kaul Barbara Zink, Ph.D., MBA
Head Public Relations & Head Corporate Development
Corporate Communications
+41 61 606 1233
+41 61 606 1460 investor_relations@basilea.com mailto:investor_relations@basilea.com
media_relations@basilea.com mailto:media_relations@basilea.com

This press release can be downloaded from www.basilea.com http://www.basilea.com/

HUG#1423867

Press release (PDF) http://hugin.info/134390/R/1423867/372613.pdf

— End of Message —

Basilea Pharmaceutica AG
Grenzacherstrasse 487
P.O Box Basel Switzerland

ISIN: CH0011432447;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Open Market (Freiverkehr) in Frankfurter Wertpapierbörse,
Freiverkehr in Bayerische Börse München;

Bookies see Europe stocks adding to recovery rally

June 14 (Reuters) – Financial bookmakers expected to see the leading European benchmark indexes rising on Monday, gaining ground for the fourth consecutive session, buoyed by gains on Wall Street and in Asia.

Stocks | European Markets | Global Markets | Financials

Financial spreadbetters expected Britain’s FTSE 100 .FTSE to open around 35 points higher, or 0.7 percent, Germany’s DAX .GDAXI to open around 40 points higher, or 0.7 percent, and France’s CAC-40 .FCHI to open around 15 points higher, or 0.4 percent.

(Reporting by Blaise Robinson)

Nissan begins limited test-drives for Leaf EV

June 11 (Reuters) – Nissan Motor Co (7201.T) on Friday kicked off a week-long test-drive event for its Leaf electric car, saying it had a combined 20,000 orders in Japan and the United States six months before the car goes on sale.

Stocks | Global Markets | Cyclical Consumer Goods

Japan’s No.3 automaker is inviting 500 journalists, shareholders, government officials, and some customers who have placed reservations to drive the five-seater hatchback at its test track near Tokyo in an exclusive preview through June 19.

Nissan is counting on the zero-emission Leaf to regain its reputation as a technology leader after trailing Toyota Motor (7203.T) and Honda Motor (7267.T) in fuel-efficient hybrid cars.

Nissan and its French partner Renault SA (RENA.PA) are the most aggressive proponents of battery-run electric cars, aiming to become the first in the world to sell them in large numbers with a global roll-out of eight models in 2012.

Ahead of the Leaf’s December launch in Japan, United States, and select European markets, Nissan hopes to dash any remaining doubts over the practicality of electric cars, whose limited driving range is seen as their biggest shortcoming.

The Leaf has a maximum listed range of 160 km (100 miles), which could be cut by half depending on traffic conditions, temperature and use of air-conditioning.

To allay “range anxiety”, the Leaf is equipped with an on-board telematics system that tells drivers how far they can go with the remaining battery power, or where the nearest charging station is.

Powered by an electric motor that runs on Nissan’s in-house developed lithium-ion batteries, the Leaf provides smooth and near-instant acceleration that engineers said was better than that of a 3.5-litre gasoline engine car.

With no engine, the car is silent. In a first for the industry, Nissan said it developed an artificial sound — a combination of a high and low-pitched hum — for the Leaf to make at speeds below 30 km/hour to alert pedestrians of its approach.

The Leaf has a sticker price of 3.76 million yen ($41,130) in Japan and is expected to cost consumers 2.99 million yen after government subsidies. Japan has not disclosed incentives policies beyond the fiscal year to end-March 2011. (Reporting by Chang-Ran Kim)

European shares seen lower on Wall St weakness

June 10 (Reuters) – European shares were expected to open sharply lower on Thursday, tracking a late overnight fall on Wall Street, ahead of interest rate decisions from the Bank of England and the European Central Bank later in the session.

Stocks | European Markets | Global Markets

Britain’s FTSE 100 .FTSE was expected to open as much as 68 points lower, or down 1.3 percent; Germany’s DAX .GDAXI was seen down 51 points, or as much as 0.9 percent, and France’s CAC 40 .FCHI was expected to fall as much as 43 points, or 1.3 percent, according to financial spreadbetters.

The pan-European FTSEurofirst 300 .FTEU3 index of top shares snapped three days of losses to close 1.9 percent higher on Wednesday.

(Reporting by Harpreet Bhal)

REFILE-UPDATE 1-Merck KGaA again seeks U.S. nod for MS pill

FRANKFURT, June 8 (Reuters) – Germany’s Merck KGaA (MRCG.DE) has resubmitted its request for U.S. regulatory approval for its cladribine drug as it tries to catch up in the race for the first multiple sclerosis (MS) pill.

Merck in February had said it met with U.S. regulators in January about the approval for cladribine but had so far not given a timetable for resubmitting the drug, which is also under review in Europe.

Merck’s shares were indicated unchanged before the German market opens at 0700 GMT on Tuesday.

Rival Swiss drugmaker Novartis AG (NOVN.VX) on April 13 moved closer to bringing the first oral MS treatment to market after new data showed its Gilenia pill cut relapse rates in the disease. [ID:nZAT010805]

Gilenia had earlier been given U.S. priority review status. U.S. experts are set to vote this week on whether to recommend approval. [ID:nLDE6530NT]

Merck KGaA had slipped behind Novartis in November after the U.S. Food and Drug Administration held up its application to bring cladribine to market. [ID:nGEE5AT1KS]

Merck had said its bid to bring the pill to European markets remained on track.

The head of Merck’s drug unit, Elmar Schnee, said on April 9 that advisers to European regulators would probably issue an assessment of the drug in the third quarter, adding he was confident about an approval. (Reporting by Ludwig Burger; Editing by Michael Shields)